{"prompt": "['Charit\u00e9 Universit\u00e4tsmedizin Berlin', 'Prof. Dr. med. Dominik Modest', 'FIRE-9 PORT', '28-Sep-2021', 'EudraCT no. 2020-006144-18', 'Protocol Version 3.0', 'Arm A and B:', 'Within the structured follow-up for up to 60 months after randomization CT scans of', 'thorax/abdomen and/or MRI scans should be scheduled every 3 months within the', '24 months after randomization. After the first two relapse-free years, intervals are', 'extended to 6 months in the third and following years after randomization.', 'Translational', 'The translational research program consists of the following steps but might be', 'research', 'modified or expanded taking latest scientific data into account:', '1.', 'Characterization of the initial resected/ablated tumor (primary and/or', 'metastases) for DNA mutations and RNA expressions (for example panel NGS', 'and mRNA expression analysis)', '2. Longitudinal assessments of tumor markers and circulating tumor DNA', '(according to initial tumor characteristics), assessments should include the', 'baseline, 3 months and 6 months timepoints (and further timepoints as long as', 'no relapse occurred).', '3.', 'Characterization of tumor specimen obtained after relapse of disease during or', 'after study (if occurring and available) for DNA mutations and RNA expressions.', '4. Correlation of 1) with 3) and eventually also correlation of relapse tumor tissue', 'with acquired changes in samples of 2)', 'This paired sample collection including relapse specimen plus the longitudinal', 'assessment of circulating tumor DNA will be performed in order to inform about early', 'detection of relapse (potentially prior to radiographic correlate), relapse patterns', '(based on initial spread and the ablative technique) and molecular background of', 'relapse (tumor evolution, secondary mutations, expressions).', 'Statistical', 'The primary endpoint will be PFS (progression-free survival, defined as', 'considerations', 'progression/relapse or death from any cause) at 24 months after randomization.', 'Our assumptions are based on the only available analysis of two pooled, early-', 'stopped trials in the adjuvant/additive setting using fluoropyrimidine monotherapies', '[Mitry et al., 2008] that reported a hazard ratio for PFS in favor of active treatment of', '0.76 (the originally reported hazard ratio was reported reversed as 1.32) that', 'translated into a similar effect for the endpoint overall survival. This again support the', 'validity of the primary endpoint PFS in this trial. We hypothesize a slightly larger', 'effect for PFS in favor of active therapy due to the 2-3 drug regimens resulting in an', 'estimated hazard ration of 0.70.', 'For the control arm (surgery alone) with structured follow-up, a', 'progression/relapse/death-free rate of 40% at time point 24 months was observed', 'translating into a 60% progression/relapse/death-rate at this time (according to the', 'reported control arm [Mitry et al., 2008]). With a hazard ratio 0.70 (=N/NC', 'C=0.0267/0.0382) favoring active treatment, the hypothesized relapse rate at 24', 'months in the intervention arm is assumed to be: 47%. With a power of 80%, a 2-', 'sided alpha of 0,05, a total of 276 events need to be observed in order to detect a', 'difference in progression-free survival of a hazard ratio of 0.70 - favoring active', 'treatment vs. observation (Schoenfeld formula). Assuming an accrual time of 48', 'months and a follow-up time of 24 months, a drop-out/censoring rate of 40% after 24', 'months after randomization, a total of 480 patients (320/160 in the respective arms,', 'rounded to receive integers and maintain the allocation ratio) is expected to yield the', 'required number of events if the accrual rate is constant. The computation was done', 'using the software R Version 3.5.1 and the package Rpact. We account for additional', '5% of patients that directly leave the study after randomization and never received', 'the study medication. Thus, a total of 507 patients (480/507~0,95) are planned to be', 'recruited.', 'Confidential', 'Page 18 of 79']['Charit\u00e9 Universit\u00e4tsmedizin Berlin', 'Prof. Dr. med. Dominik Modest', 'FIRE-9 PORT', '28-Sep-2021', 'EudraCT no. 2020-006144-18', 'Protocol Version 3.0', 'Duration and', 'Recruitment', 'end of trial', 'First patient in (FPI) to Last patient in (LPI): 48 months', 'Analysis', 'Primary endpoint (PFS) at 24 months', 'after randomization:', 'LPI + 24 months (72 months total)', 'Secondary endpoints:', 'LPI + 60 months (108 months total)', 'End of Study (EOS)', 'Last visit of last patient (LVLP)', 'Last patient in (LPI) + 60 months', '(FPI + 108 months in total)', 'GCP statement', 'This clinical trial will be conducted in accordance with the ethical principles that', 'have their origin in the Declaration of Helsinki and that are consistent with the', 'International Conference on Harmonization (ICH) for Good Clinical Practice (GCP)', 'and the applicable regulatory requirements.', 'Confidential', 'Page 19 of 79']\n\n###\n\n", "completion": "END"}